Your browser doesn't support javascript.
loading
Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era.
Karlin, Kirill; Bryke, Christine; Dias, Ajoy; Michaels, Phillip.
Afiliación
  • Karlin K; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
  • Bryke C; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
  • Dias A; Department of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
  • Michaels P; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Leuk Res Rep ; 17: 100320, 2022.
Article en En | MEDLINE | ID: mdl-35572917
Acute promyelocytic leukemia (APL) is a unique leukemia that is characterized by the PML::RARA fusion. This fusion is often detected by conventional karyotype and fluorescence in situ hybridization (FISH); however, rare cases are cryptic and require molecular techniques to identify the PML::RARA fusion. Furthermore, as the incidence of these cases is rare, analysis by a targeted next-generation sequencing (NGS) panel of myeloid associated genes has never been reported. Herein, a clinical APL case is reported where the PML::RARA fusion was detected only by reverse transcriptase-polymerase chain reaction (RT-PCR), thus underscoring the necessity of utilizing complementary techniques when suspicion for APL is present.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Leuk Res Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Leuk Res Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos